Prognostic Significance of a Scoring System Combining p16, Smoking, and Drinking Status in a Series of 131 Patients with Oropharyngeal Cancers.

Journal

International journal of otolaryngology
ISSN: 1687-9201
Titre abrégé: Int J Otolaryngol
Pays: United States
ID NLM: 101518366

Informations de publication

Date de publication:
2021
Historique:
received: 31 05 2021
accepted: 31 08 2021
entrez: 17 9 2021
pubmed: 18 9 2021
medline: 18 9 2021
Statut: epublish

Résumé

Tobacco and alcohol are two main risk factors associated with head and neck squamous cell carcinoma (HNSCC). Studies showed that human papillomavirus (HPV) plays a role in the etiology of this cancer. HPV-positive oropharyngeal squamous cell carcinoma (OSCC) patients present in general a better response to conventional therapy and better overall survival (OS). However, OSCC is a heterogeneous disease regarding treatment. This study aimed to identify more effective prognostic factors associated with a poor clinical outcome for OSCC patients to improve treatment selection. OSCC patients diagnosed between 2007 and 2017, in two Belgian hospitals, were included. Demographic and clinicopathologic data were extracted from medical records. HPV status was determined through p16 immunohistochemistry. Univariable and multivariable Cox proportional hazard regression analyses allowed to identify variables prognostic for OS and recurrence-free survival (RFS). Kaplan-Meier survival curves have been assessed for survival. The study included 131 patients. Statistics showed that monotherapies were significantly associated with a shorter OS; p16 overexpression was significantly associated with a weak consumption of tobacco or alcohol, and a high p16 expression was significantly associated with both longer RFS and OS. The study validated that tobacco and alcohol consumption were significantly correlated with poorer RFS and poorer OS. Only p16 expression trended to be significant for RFS when compared to smoking and drinking habits, while p16 upregulation and alcohol use were both vital for OS indicating that p16 is an independent and significant prognostic factor in OSCC patients. Finally, a scoring system combining p16, tobacco, and alcohol status was defined and was significantly associated with longer RFS and longer OS for nonsmoker and nondrinker p16-positive OSCC patients. This study confirmed that the overexpression of the p16 protein could be viewed as a factor of good prognosis for RFS and OS of OSCC patients. The prognostic significance of a scoring system combining p16 expression, smoking, and drinking status was evaluated and concluded to be a more effective tool to determine therapeutic orientations based on the risk factors for better treatment relevance and survival.

Sections du résumé

BACKGROUND BACKGROUND
Tobacco and alcohol are two main risk factors associated with head and neck squamous cell carcinoma (HNSCC). Studies showed that human papillomavirus (HPV) plays a role in the etiology of this cancer. HPV-positive oropharyngeal squamous cell carcinoma (OSCC) patients present in general a better response to conventional therapy and better overall survival (OS). However, OSCC is a heterogeneous disease regarding treatment. This study aimed to identify more effective prognostic factors associated with a poor clinical outcome for OSCC patients to improve treatment selection.
MATERIALS AND METHODS METHODS
OSCC patients diagnosed between 2007 and 2017, in two Belgian hospitals, were included. Demographic and clinicopathologic data were extracted from medical records. HPV status was determined through p16 immunohistochemistry. Univariable and multivariable Cox proportional hazard regression analyses allowed to identify variables prognostic for OS and recurrence-free survival (RFS). Kaplan-Meier survival curves have been assessed for survival.
RESULTS RESULTS
The study included 131 patients. Statistics showed that monotherapies were significantly associated with a shorter OS; p16 overexpression was significantly associated with a weak consumption of tobacco or alcohol, and a high p16 expression was significantly associated with both longer RFS and OS. The study validated that tobacco and alcohol consumption were significantly correlated with poorer RFS and poorer OS. Only p16 expression trended to be significant for RFS when compared to smoking and drinking habits, while p16 upregulation and alcohol use were both vital for OS indicating that p16 is an independent and significant prognostic factor in OSCC patients. Finally, a scoring system combining p16, tobacco, and alcohol status was defined and was significantly associated with longer RFS and longer OS for nonsmoker and nondrinker p16-positive OSCC patients.
CONCLUSIONS CONCLUSIONS
This study confirmed that the overexpression of the p16 protein could be viewed as a factor of good prognosis for RFS and OS of OSCC patients. The prognostic significance of a scoring system combining p16 expression, smoking, and drinking status was evaluated and concluded to be a more effective tool to determine therapeutic orientations based on the risk factors for better treatment relevance and survival.

Identifiants

DOI: 10.1155/2021/8020826 PMID: 34531914 PMC: PMC8440106
pubmed: 34531914
doi: 10.1155/2021/8020826
pmc: PMC8440106
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

8020826

Informations de copyright

Copyright © 2021 Cyril Bouland et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Cancer Res. 2014 Mar 15;74(6):1739-51
pubmed: 24473065
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Ann Oncol. 2018 May 1;29(5):1273-1279
pubmed: 29438466
Neoplasma. 2012;59(4):398-408
pubmed: 22489695
Oral Oncol. 2010 Jul;46(7):497-503
pubmed: 20444641
J Clin Pathol. 2020 Oct;73(10):624-629
pubmed: 32499224
Head Neck Pathol. 2020 Jun;14(2):321-329
pubmed: 32124415
J Clin Oncol. 2006 Jun 10;24(17):2606-11
pubmed: 16763272
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
J Clin Oncol. 2013 Feb 10;31(5):543-50
pubmed: 23295795
J Cancer Res Clin Oncol. 2016 Oct;142(10):2185-96
pubmed: 27370781
Mayo Clin Proc. 2008 Apr;83(4):489-501
pubmed: 18380996
Biomed Res Int. 2018 Sep 17;2018:9594568
pubmed: 30310820
Radiother Oncol. 2010 Jun;95(3):371-80
pubmed: 20493569
Br J Cancer. 2014 Mar 18;110(6):1587-94
pubmed: 24518594
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Br J Cancer. 2013 Apr 2;108(6):1332-9
pubmed: 23412100
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Oral Oncol. 2018 Jun;81:89-94
pubmed: 29884419
Int J Cancer. 2017 Mar 1;140(5):1186-1198
pubmed: 27859245
Int J Cancer. 2014 Nov 15;135(10):2404-12
pubmed: 24706381
Cancer. 2019 Mar 1;125(5):704-711
pubmed: 30548235

Auteurs

Cyril Bouland (C)

Department of Stomatology-Maxillofacial Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Didier Dequanter (D)

Department of Stomatology-Maxillofacial Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Otolaryngolology-Head & Neck Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.
ORCID: 0000-0002-2420-285X

Jérôme R Lechien (JR)

Department of Otolaryngolology-Head & Neck Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Thoracic-Head & Neck Surgery, Centre Oscar Lambret, Lille, France.
Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Mons, Belgium.

Charlotte Hanssens (C)

Department of Stomatology-Maxillofacial Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Nicolas De Saint Aubain (N)

Department of Pathology, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Antoine Digonnet (A)

Department of Head and Neck Surgery, Jules Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Rokneddine Javadian (R)

Department of Stomatology-Maxillofacial Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Antoine Yanni (A)

Department of Stomatology-Maxillofacial Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Alexandra Rodriguez (A)

Department of Otolaryngolology-Head & Neck Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Isabelle Loeb (I)

Department of Stomatology-Maxillofacial Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Fabrice Journe (F)

Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Mons, Belgium.
Laboratory of Oncology and Experimental Surgery, Bordet Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Sven Saussez (S)

Department of Otolaryngolology-Head & Neck Surgery, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMONS), Mons, Belgium.

Classifications MeSH